PHC-HOLDINGS-CORPORATION
PHC Holdings Corporation (headquarters: Minato-ku Tokyo, Japan, hereafter PHCHD) has today announced that Michael Kloss has taken up the position of President and CEO of PHCHD effective April 1, 2019. Michael succeeds Hidehito Kotani, who has today stepped down as President and CEO.
With more than 20-years of experience in the healthcare industry, Michael Kloss joined PHCHD in 2016 following the acquisition of diabetes care business from Bayer AG and became President and CEO of the newly founded Ascensia Diabetes Care Holdings AG. He has led the diabetes care business throughout the sale from Bayer and has helped to establish Ascensia as a leading diabetes care solutions company.
At an inauguration speech at PHCHD in Tokyo today, Michael Kloss officially stated, “As I take over this role as CEO of PHCHD, we are entering an immensely exciting time for the company. Our ambition is to build a healthcare company with leading global businesses in diabetes care, diagnostics and life sciences alongside a strong healthcare solutions business in Japan. We will achieve this by growing our existing business segments and identifying new ways to expand our products and services. This will enable us to successfully deliver on our mission to contribute to the wellbeing of society by providing solutions for people who wish for better health.”
Michael explained, “The journey for PHCHD started in 2014, when our business carved out from Panasonic group and we set up a Panasonic Healthcare. Since then we have acquired the diabetes care business from Bayer to establish Ascensia Diabetes Care, experienced steady growth across our business segments, and changed our name to PHC Holdings. We are now about to move into the next transformative phase in the development of our company with the proposed addition of the Anatomical Pathology business from Thermo Fisher. Through this potential acquisition, we are adding a new and highly successful business that is showing considerable growth.”
PHC Holdings currently offers value-added products and services through three core businesses: Medical Devices, Life Sciences and Healthcare IT. In January 2019, PHCHD announced the signing of an agreement to acquire the Anatomical Pathology business from Thermo Fisher.
Michael added, “I am thrilled and honored to be taking over this role leading PHCHD and look forward to working with our highly talented employees to successfully grow our business. We have a world-class portfolio of state-of-the-art products and an innovative pipeline of new solutions that can address the unmet needs in healthcare. Our priority is to continue to deliver new value to our customers that will help to build a future of better healthcare for people across the world.”
About PHC Holdings Corporation
Incorporated in 2014, PHC Holdings Corporation is a global healthcare company. Its subsidiaries include PHC Corporation and Ascensia Diabetes Care Holdings AG. Committed to its corporate mission, “We contribute to the wellbeing of society through our diligent efforts by creating new value propositions for all the people who wish for better health,” the company develops, manufactures, sells and services medical equipment and solutions across diabetes care, diagnostics, life sciences and healthcare IT. PHC Holdings Corporation group’s consolidated net sales in FY2017 was 192.6 billion yen with global distribution of products and services for more than 125 countries.
For further information on PHC Holdings Corporation, please visit www.phchd.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190401005284/en/
Contact:
Corporate Communications Group PHC Holdings Corporation Masayo Okada, +81-3-6778-5311
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EIG Acquires a 49.87% Stake in Transportadora de Gas del Perú (TgP)19.12.2025 18:42:00 CET | Press release
EIG, through its managed investment vehicles, acquired a 49.87% equity stake in Transportadora de Gas del Perú S.A. (“TgP”) from Canada Pension Plan Investment Board today. TgP operates Peru’s principal natural gas and natural gas liquids pipelines under a long-term concession, supplying approximately 40% of the country’s power generation. “We are delighted to complete this transaction and embark on the next chapter of our partnership with TgP,” said Matt Hartman, EIG’s Global Head of Infrastructure. “Our priority is to support TgP’s operational excellence and long-term stability, delivering value for customers and stakeholders throughout Peru.” About EIG EIG is a leading institutional investor in the global energy and infrastructure sectors with $24.3 billion assets under management as of September 30, 2025. EIG specializes in private investments in energy and energy-related infrastructure on a global basis. During its 43-year history, EIG has committed over $51.7 billion to the energ
CyberArk Named a Leader in IDC MarketScape: Worldwide Integrated Solutions for Identity Security 202519.12.2025 17:00:00 CET | Press release
Unified platform uses AI and automation to accelerate time-intensive workflows, streamline operations and improve threat detectionEnables CISOs to consolidate cybersecurity stack, optimizing total cost of ownership CyberArk (NASDAQ: CYBR), the global leader in identity security, today announced that it has been recognized as a Leader in the IDC MarketScape: Worldwide Integrated Solutions for Identity Security 2025 Vendor Assessment. CyberArk extends dynamic privilege controls across all identity types with its unified platform, enabling organizations to improve efficiencies and streamline security operations. This IDC MarketScape report notes, “More change has occurred in the identity security marketplace in the past two years than in almost a decade. Vendors are entering a new phase defined by the emergence of intelligence technologies, none of which are specifically defined by any industry standards. Though different by design, the new adjacent IAM offerings are largely focused on im
New York Liberty and Ant International’s Alipay+ Announce Multiyear Partnership Focused on Empowerment, Sustainability and Youth Development19.12.2025 14:30:00 CET | Press release
Ant International’s Alipay+ Named an Official Sponsor and Innovation Partner for Sustainability of the Team The New York Liberty and Ant International’s Alipay+, a leading cross-border fintech services platform based in Singapore, today announced a multiyear partnership, making Alipay+ an Official Sponsor and Innovation Partner for Sustainability of the New York Liberty. Through this partnership, Alipay+ and the Liberty will jointly support community programs designed to advance community empowerment, environmental sustainability and youth development across New York City. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219678825/en/ Peng Yang, CEO, Ant International and Clara Wu Tsai, Vice Chair, Brooklyn Sports and Entertainment; Governor, New York Liberty “Our partnership with Alipay+ goes beyond the game,” said Keia Clarke, Chief Executive Officer, New York Liberty. “Together, we are investing in the future of New York
Parse Biosciences and Codebreaker Labs Partner to Apply Whole Transcriptome Single Cell Profiling and Causal Genomics at Scale19.12.2025 14:00:00 CET | Press release
Collaboration pairs robust synthetic biology platform with massive scale single cell sequencing to overcome long-standing challenges in variant mapping Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a collaboration with Codebreaker Labs to develop and validate a breakthrough platform capable of testing thousands of genetic variants in parallel and measuring their effects at single cell resolution. By combining Codebreaker’s synthetic biology platform and variant engineering capabilities with the scale and accessibility of Parse’s Evercode™ technology, the collaboration aims to generate the causal data increasingly sought by AI developers, drug discovery teams, and clinical researchers. Today’s genomic studies rely heavily on observational data, or variants that appear in large populations. But rare and private variants, often only seen in one individual or family, are nearly impossible to study this way because too f
Cinemo Launches Cinemo ICO™, Accelerating the AI-Driven Intelligent Cockpit19.12.2025 11:00:00 CET | Press release
The future of in-car intelligence, delivered today for hyper-personalized, safer, smarter, and more exceptional journeys Cinemo, a global leader and highly innovative one-stop-shop provider for fully integrated digital media products announces today the launch of its next-generation, AI-powered cockpit solutions - Cinemo ICO™. By bringing agentic AI, Cinemo unlocks a truly intelligent cockpit - connecting vehicles, drivers, passengers, and their digital ecosystems into one seamless, personal and context-aware flow. The first product launched within the Cinemo ICO™ portfolio is Cinemo ICO™ MediaMind, enabling advanced intelligent media discovery. It combines the latest agentic AI technology with Cinemo’s core expertise of providing automotive-grade media management, helping users effortlessly discover the right content for every ride - perfectly matched to their taste, context, and environment. With Cinemo ICO™ MediaMind, the digital media experience evolves: using cutting-edge large la
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom